$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416131686 Filed on November 04, 2016

Income Statement

Concept	2016 Q3	2015 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.50M	$2.680M
YoY Change	291.79%	185.11%
% of Gross Profit
Research & Development	$8.481M	$4.960M
YoY Change	70.99%	1301.13%
% of Gross Profit
Depreciation & Amortization	$150.0K	$266.0K
YoY Change	-43.61%	5220.0%
% of Gross Profit
Operating Expenses	$18.98M	$7.643M
YoY Change	148.32%	172.67%
Operating Profit	-$18.98M	-$7.643M
YoY Change	148.32%	172.67%
Interest Expense	$220.0K	$10.00K
YoY Change	2100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.76M	-$7.640M
YoY Change	145.55%	172.86%
Income Tax
% Of Pretax Income
Net Earnings	-$68.21M	-$7.635M
YoY Change	793.41%	153.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$317.4K	-$161.6K
COMMON SHARES
Basic Shares Outstanding	58.44M shares	47.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$179.3M	$110.1M
YoY Change	62.85%	540.12%
Cash & Equivalents	$92.90M	$30.77M
Short-Term Investments	$86.40M	$79.40M
Other Short-Term Assets	$1.300M	$200.0K
YoY Change	550.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$180.6M	$110.4M
YoY Change	63.56%	541.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.769M	$1.833M
YoY Change	-3.49%	816.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.769M	$1.833M
YoY Change	-3.49%	816.5%
TOTAL ASSETS
Total Short-Term Assets	$180.6M	$110.4M
Total Long-Term Assets	$1.769M	$1.833M
Total Assets	$182.3M	$112.2M
YoY Change	62.47%	544.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$228.0K	$1.161M
YoY Change	-80.36%	93.5%
Accrued Expenses	$2.966M	$1.608M
YoY Change	84.45%	221.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.194M	$2.855M
YoY Change	11.87%	119.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.194M	$2.855M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$3.200M	$2.900M
YoY Change	10.34%	123.08%
SHAREHOLDERS EQUITY
Retained Earnings		-$95.85M
YoY Change
Common Stock	$3.000K	$2.000K
YoY Change	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$179.1M	$109.4M
YoY Change
Total Liabilities & Shareholders Equity	$182.3M	$112.2M
YoY Change	62.44%	544.97%

Cashflow Statement

Concept	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$68.21M	-$7.635M
YoY Change	793.41%	153.32%
Depreciation, Depletion And Amortization	$150.0K	$266.0K
YoY Change	-43.61%	5220.0%
Cash From Operating Activities	-$12.21M	-$3.840M
YoY Change	217.97%	121.97%
INVESTING ACTIVITIES
Capital Expenditures	-$720.0K	-$70.00K
YoY Change	928.57%	-56.25%
Acquisitions
YoY Change
Other Investing Activities	-$15.63M	$20.42M
YoY Change	-176.54%
Cash From Investing Activities	-$16.35M	$20.35M
YoY Change	-180.34%	-12818.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K	1.710M
YoY Change	-70.76%	167.19%
NET CHANGE
Cash From Operating Activities	-12.21M	-3.840M
Cash From Investing Activities	-16.35M	20.35M
Cash From Financing Activities	500.0K	1.710M
Net Change In Cash	-28.06M	18.22M
YoY Change	-254.01%	-1557.6%
FREE CASH FLOW
Cash From Operating Activities	-$12.21M	-$3.840M
Capital Expenditures	-$720.0K	-$70.00K
Free Cash Flow	-$11.49M	-$3.770M
YoY Change	204.77%	140.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	277000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	103977000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1676000	USD
CY2015Q4	us-gaap	Assets Assets	105653000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	958000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	672000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1630000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	180556000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1769000	USD
CY2016Q3	us-gaap	Assets Assets	182325000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	228000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2966000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3194000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2016Q3	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1274000	USD
CY2015Q4	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	163000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92895000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105653000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47272000	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	115000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19262000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8481000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	18979000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37091000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	81000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	511000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20517000	USD
CY2015Q3	us-gaap	Revenues Revenues	0	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4960000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7643000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7643000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18979000	USD
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	8000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	221000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-7635000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-18758000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59113000	shares
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10498000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2683000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	85000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18673000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7619000	USD
	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-624000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	478000	USD
	lbio	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	879000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	44009000	USD
	lbio	Preferredstocksoldinprivateplacementvalue Preferredstocksoldinprivateplacementvalue	51676000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	997000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1294000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	110249000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94159000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16871000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	879000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	96688000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	59308000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	115000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	688000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	691000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	163000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1193000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11801000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	95236000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	15900000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	992000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-80328000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9618000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77992000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14137000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44909000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30772000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	48000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	478000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	354000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	95685000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	68308000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	179300000	USD
CY2016Q3	lbio	Working Capital WorkingCapital	177400000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	100000000	USD
CY2016Q3	us-gaap	Trading Securities Cost TradingSecuritiesCost	174880000	USD
CY2016Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	175043000	USD
	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	177000	USD
	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	-14000	USD
CY2015Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	90010000	USD
CY2015Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	90058000	USD
CY2015	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	48000	USD
CY2015	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5778000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	15781000	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2388000	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	8645000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	70113000	USD
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	86387000	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61948389	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61948389	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48547720	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48547720	shares
CY2016Q3	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	303125	shares
CY2015Q4	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	303125	shares
CY2016Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	49454000	USD
CY2015Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	49454000	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68212000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7635000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86660000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19300000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15781000	USD
	lbio	Stock Cancelled During Period Restricted Shares Value StockCancelledDuringPeriodRestrictedSharesValue	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-49454000	USD
	lbio	Adjustments To Additional Paid In Capital Preferred Stock With Conversion Feature AdjustmentsToAdditionalPaidInCapitalPreferredStockWithConversionFeature	49454000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	-69000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15781000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5778000	USD
	lbio	Deemed Dividend Related To Beneficial Conversion Feature DeemedDividendRelatedToBeneficialConversionFeature	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of available-for-sale investments, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21106414	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12282411	shares
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	86387000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	70113000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	86224000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	321252	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	272084	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	40001	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	9167	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2016Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	49500000	USD
CY2016Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	500000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.1138	pure
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	39000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	610000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0157	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0157	pure
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	629000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	633000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	495000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	169000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2575000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2100000	USD
CY2016Q3	lbio	Lease Expiration Term LeaseExpirationTerm	P54M
CY2016Q3	us-gaap	Area Of Land AreaOfLand	8733	sqft
CY2016Q3	lbio	Commitments For Quarterly Payments CommitmentsForQuarterlyPayments	500000	USD
CY2016Q3	lbio	Commitments For Payments Over Life Of Amendment CommitmentsForPaymentsOverLifeOfAmendment	10000000	USD
CY2016Q2	lbio	Common Stock Registered For Resale CommonStockRegisteredForResale	128500	shares
	us-gaap	License Costs LicenseCosts	600000	USD
	us-gaap	License Costs LicenseCosts	400000	USD
CY2016Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	3421960	shares
CY2013Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100
CY2016Q1	lbio	Shares Sold Under Ineffective Registration SharesSoldUnderIneffectiveRegistration	128500	shares

Files In Submission

Name	View Source	Status
0001144204-16-131686-index-headers.html	Edgar Link	pending
0001144204-16-131686-index.html	Edgar Link	pending
0001144204-16-131686.txt	Edgar Link	pending
0001144204-16-131686-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lbio-20160930.xml	Edgar Link	completed
lbio-20160930.xsd	Edgar Link	pending
lbio-20160930_cal.xml	Edgar Link	unprocessable
lbio-20160930_def.xml	Edgar Link	unprocessable
lbio-20160930_lab.xml	Edgar Link	unprocessable
lbio-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v451596_10q.htm	Edgar Link	pending
v451596_ex10-3.htm	Edgar Link	pending
v451596_ex10-5.htm	Edgar Link	pending
v451596_ex31-1.htm	Edgar Link	pending
v451596_ex31-2.htm	Edgar Link	pending
v451596_ex32-1.htm	Edgar Link	pending
v451596_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q3 Form 10-Q Financial Statement

#000114420416131686 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q3 Form 10-Q Financial Statement

#000114420416131686 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova